Avalo Therapeutics (AVTX) Cash from Operations (2014 - 2026)

Avalo Therapeutics (AVTX) has 13 years of Cash from Operations data on file, last reported at 17700000.0 in Q1 2026.

• Quarterly Cash from Operations fell 87.16% year-over-year to 17700000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 59743000.0 (down 14.21% YoY) and the FY2025 annual result came in at 51500000.0, down 4.98% from the prior year.
• Cash from Operations fell to 17700000.0 in Q1 2026, from 14288000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 5726000.0 in Q3 2022 to a low of 17700000.0 in Q1 2026.
• A 5-year average of 10334529.41 and a median of 11343000.0 in 2025 frame the typical range for Cash from Operations.
• Annual changes were most pronounced in 2022 — Cash from Operations soared 135.15% — and 2024, when it tumbled 443.89%.
• Tracing AVTX's Cash from Operations over 5 years: stood at 3940000.0 in 2022, then advanced by 29.8% to 2766000.0 in 2023, then plunged by 443.89% to 15044000.0 in 2024, then climbed by 5.03% to 14288000.0 in 2025, then fell by 23.88% to 17700000.0 in 2026.
• The last three Cash from Operations figures came in at 17700000.0 (Q1 2026), 14288000.0 (Q4 2025), and 16412000.0 (Q3 2025), per Business Quant data.